Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative ...

Proteasomes are molecular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies. This story was originally published on BioPharma Dive. To receive ...

A new active substance attacks a key protein in tumor cells, leading to complete degradation. In cell experiments, this caused cancer cells to lose their protection and die. The active substance was ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

Targeted protein degradation has moved well beyond its prologue more than 20 years ago. 1 The number of publications describing different PROTACs (PROteolysis TArgeting Chimeras), molecular glues, and ...

Researchers have developed smart nanoparticles that can seek out and destroy disease-causing proteins the body can’t normally eliminate. Unlike traditional drugs, these particles can reach ...

What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...

Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural protein disposal systems to eliminate disease-causing proteins. Innovators are making rapid and ...

Researchers developed nanotechnology that selectively binds and degrades abnormal proteins. The technology shows promise for ...

Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining Investment will support further development of ...

Innovative Agents Highlight Growth of Targeted Protein Degradation Platform and BMS' Leadership in Innovative Cancer Therapies The latest data presented for the three lead CELMoD agents and BCL6 LDD ...